durvalumab,tremelimumab
astrazeneca
[]
the #oncoalerttoptweet for day1 #gi23 tweet #infinity trial
neoadj durva/tremi in pts with dmmr g/gej cancers. very promising data in another dmmr population in the neoadjuvant setting #gi23 best, 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨